Stockscreener 앱 받기
791.09
0.85%
6.24
전일 마감가:
$784.85
열려 있는:
$786.03
하루 거래량:
78,159
Relative Volume:
0.10
시가총액:
$81.46B
수익:
$14.92B
순이익/손실:
$4.42B
주가수익비율:
19.28
EPS:
41.0422
순현금흐름:
$3.79B
1주 성능:
-0.28%
1개월 성능:
-5.10%
6개월 성능:
+8.00%
1년 성능:
+33.70%
1일 변동 폭
$779.96
$792.68
1주일 범위
$769.57
$794.73
52주 변동 폭
$541.00
$859.34
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
791.26 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
511.08 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
167.93 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
998.52 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
366.00 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-31 | 재개 | Piper Sandler | Overweight |
| 2026-03-06 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2025-12-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 개시 | HSBC Securities | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-14 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds - The National Law Review
REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - PR Newswire
REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Invest - The National Law Review
REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - GlobeNewswire Inc.
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth - Yahoo Finance
Is Regeneron (NASDAQ:REGN) Entering A New Phase? - Kalkine Media
INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investo - The National Law Review
Regeneron stock dips ahead of class action deadline - ad-hoc-news.de
REGN SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron I - The National Law Review
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Why Is Regeneron Pharmaceuticals (REGN) Facing A New Investor Lawsuit? - simplywall.st
Regeneron stock heads into the open after a 1.8 percent drop - ad-hoc-news.de
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Best Biotech Stocks To Add to Your WatchlistSeptember 10th - MarketBeat
Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says - marketscreener.com
REGN Maintained by HSBC -- Price Target Raised to $920 - GuruFocus
Regeneron stock gains after strong Q2 2026 earnings beat - ad-hoc-news.de
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesREGN - PR Newswire
REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE - GlobeNewswire
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. LawsuitREGN - PR Newswire
Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Seek Counsel Before the September 14, 2026 Lead Plaintiff Deadline in the Securities Class Action - PR Newswire
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
REGN MONDAY DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - PR Newswire
Mathai Mammen on Betting on Big Swings to Drug the Undruggable - finance.biggo.com
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bronstein, Gewirtz & Grossman LLC Urges Regeneron - globenewswire.com
Here’s Why The Fund Sold Regeneron Pharmaceuticals (REGN) - Yahoo Finance
Regeneron at Wells Fargo healthcare conference: growth broadens By Investing.com - Investing.com UK
Levi & Korsinsky Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026REGN - PR Newswire
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 08:45 AM - marketscreener.com
Regeneron Pharmaceuticals, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $920 From $800, Keeps Outperform Rating - marketscreener.com
Why is Regeneron Pharmaceuticals (NASDAQ:REGN) drawing investor attention today? - Kalkine Media
(REGN) Volatility Zones as Tactical Triggers - Stock Traders Daily
REGN 6-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - GlobeNewswire Inc.
Did Libtayo Recall Just Shift Regeneron's (REGN) Investment Narrative? - simplywall.st
Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock - Yahoo Finance
REGENERNON PHARMACEUTICALS, INC. (REGN) SHAREHOLDER ALERT - GlobeNewswire
REGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Regeneron stock holds firm after strong Q2 2026 results - AD HOC NEWS
MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 DeadlineRGRD Law - marketscreener.com
3 Reasons to Avoid REGN and 1 Stock to Buy Instead - The Globe and Mail
1 WEEK REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - TMX Newsfile
REGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Re - natlawreview.com
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Regeneron stock holds near lofty levels as class action risk emerges - AD HOC NEWS
REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before September 14, 2026 Deadline - newsfilecorp.com
Regeneron stock slips on a $85.2 billion market value - ad-hoc-news.de
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Eastern Progress
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
리제네론 파마슈티컬스 주식 (REGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial |
Sep 03 '26 |
Sale |
857.39 |
1,131 |
969,708 |
12,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Option Exercise |
719.37 |
400 |
287,748 |
1,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Sale |
850.00 |
400 |
340,000 |
603 |
9.77%
자본화:
|
볼륨(24시간):